Regenxbio (NASDAQ:RGNX) just reported results for the first quarter of 2024.
- Regenxbio reported earnings per share of -$1.38. This was below the analyst estimate for EPS of -$1.26.
- The company reported revenue of $15.62 million.
- This was 33.58% worse than the analyst estimate for revenue of $23.52 million.